{"filing":{"accession_number":"0001437749-26-018318","cik":"0001595248","ticker":"GNPX","company_name":"Genprex, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"gnpx20260515_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926018318/gnpx20260515_8k.htm"},"events":[{"id":9086,"run_id":7978,"accession_number":"0001437749-26-018318","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Genprex announced publication of a peer-reviewed abstract at the 2026 ASCO Annual Meeting presenting positive clinical data from its Acclaim trials showing that high Trop-2 and low PTEN biomarkers correlate with prolonged PFS in NSCLC patients receiving Reqorsa gene therapy. While this is clinical validation of a lead drug candidate and biomarker discovery that would be material to investors assessing development progress, it does not fit neatly into the standard 8-K taxonomy—it is neither an earnings release, M\u0026A activity, executive change, restatement, nor other specifically enumerated event. The disclosure represents material clinical progress and biomarker validation that would affect a reasonable investor's assessment of the company's pipeline advancement.","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1583,"accession_number":"0001437749-26-018318","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Genprex announced publication of a peer-reviewed abstract at the 2026 ASCO Annual Meeting presenting positive clinical data from its Acclaim trials showing that high Trop-2 and low PTEN biomarkers correlate with prolonged PFS in NSCLC patients receiving Reqorsa gene therapy. While this is clinical validation of a lead drug candidate and biomarker discovery that would be material to investors assessing development progress, it does not fit neatly into the standard 8-K taxonomy—it is neither an earnings release, M\u0026A activity, executive change, restatement, nor other specifically enumerated event. The disclosure represents material clinical progress and biomarker validation that would affect a reasonable investor's assessment of the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:32:09.536198+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1583,"accession_number":"0001437749-26-018318","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Genprex announced publication of a peer-reviewed abstract at the 2026 ASCO Annual Meeting presenting positive clinical data from its Acclaim trials showing that high Trop-2 and low PTEN biomarkers correlate with prolonged PFS in NSCLC patients receiving Reqorsa gene therapy. While this is clinical validation of a lead drug candidate and biomarker discovery that would be material to investors assessing development progress, it does not fit neatly into the standard 8-K taxonomy—it is neither an earnings release, M\u0026A activity, executive change, restatement, nor other specifically enumerated event. The disclosure represents material clinical progress and biomarker validation that would affect a reasonable investor's assessment of the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:32:09.536198+00:00","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-05-26"}]}